Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter
Welcure Drugs & Pharmaceuticals Ltd 路 Financial Result 路 30 May 2026, 1:39 am
Welcure Drugs FY26: Posts Net Loss Amid Auditor's Emphasis of Matter Welcure Drugs reported a net loss of Rs 549.01 Lacs for the year ended 31st Mar'26, against a profit of Rs 217.01 Lacs in the previous year. For Q4 FY26, the company posted a net loss of Rs 4,986.14 Lacs. The statutory auditor issued an unmodified opinion but included an "Emphasis of Matters" section, highlighting an inability to verify the existence and valuation of inventory (Rs 14,352.36 Lacs), genuineness of certain sales, and recoverability of trade receivables and unconfirmed supplier advances (Rs 15,126.13 Lacs).
Original exchange filing (PDF)
More announcements from Welcure Drugs & Pharmaceuticals Ltd
- Approval of the Audited Standalone Financial Results and Audited Standalone Financial Statements 路 02 Nov 2026
- Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday, 14th July, 2026. 路 14 Jul 2026
- Resignation of Company Secretary and Compliance Officer 路 19 Jun 2026
- Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday, 19th June, 2026 路 19 Jun 2026
- Outcome of the Meeting of Board of Directors of the Company held on today i.e. Friday, 29th May, 2026 路 30 May 2026
- Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial .... 路 29 May 2026
- <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... 路 23 Apr 2026
- Unaudited Financials Results for the 3rd Quarter ended on 31st December, 2025 路 13 Feb 2026
